Effects of the kappa opioid agonist U50,488 and the kappa opioid antagonist nor-binaltorphimine on choice between cocaine and food in rhesus monkeys

2004 ◽  
Vol 176 (2) ◽  
pp. 204-213 ◽  
Author(s):  
S. Stevens Negus
Keyword(s):  
Rhesus Monkeys ◽  
Opioid Antagonist ◽  
Opioid Agonist ◽  
Kappa Opioid ◽  
Kappa Opioid Agonist

kappa-Opioid agonist inhibition of osmotically induced AVP release: preferential action at hypothalamic sites

1996 ◽  
Vol 270 (2) ◽  
pp. E367-E372 ◽  
Author(s):  
N. F. Rossi ◽  
D. P. Brooks
Keyword(s):  
Potent Inhibitor ◽  
Opiate Receptors ◽  
Opioid Antagonist ◽  
Posterior Pituitary ◽  
Opioid Agonist ◽  
Kappa Opioid ◽  
Water Diuresis ◽  
Kappa Agonist ◽  
Opioid Agonists ◽  
Kappa Opioid Agonist

Although several studies indicate that kappa-opioid agonists induce a water diuresis by inhibiting vasopressin (AVP) secretion, the locus of the kappa-receptors (neurohypophysial vs. hypothalamic) responsible for this effect remains unclear. We have ascertained the effect of the selective kappa-agonist BRL-52656 (BRL) on AVP secretion by using compartmentalized rat hypothalamoneurohypophysial explants in culture. When applied to the hypothalamus, nanomolar concentrations of BRL inhibited osmotically stimulated AVP secretion. This response was blocked by the highly selective kappa-opioid antagonist nor-binaltorphimine (BNI). However, osmotically stimulated AVP release was suppressed at the neurohypophysial site only by 100 nM BRL and was not reversed by BNI but only by naloxone. This dose of BRL, administered to the posterior pituitary compartment, did not appear to act by the agonist gaining access to hypothalamic kappa-opiate receptors, because BNI added to the hypothalamus failed to prevent the inhibition of AVP secretion. The data demonstrate that BRL is a potent inhibitor of osmotically stimulated AVP secretion via activation of kappa-opiate receptors within the hypothalamus, but that higher concentrations of the drug may also stimulate non-kappa-neurohypophysial opiate receptors that suppress AVP release.

scholarly journals Acute delta- and kappa-opioid agonist pretreatment potentiates opioid antagonist-induced suppression of water consumption

2008 ◽  
Vol 76 (6) ◽  
pp. 597-604 ◽  
Author(s):  
David A. White ◽  
Michael E. Ballard ◽  
Alvin C. Harmon ◽  
Stephen G. Holtzman
Keyword(s):  
Water Consumption ◽  
Opioid Antagonist ◽  
Opioid Agonist ◽  
Kappa Opioid ◽  
Kappa Opioid Agonist

scholarly journals Pain‐related depression of intracranial self‐stimulation in rats: effects of the kappa opioid agonist U69,593 and the kappa opioid antagonist norbinaltorphimine

2010 ◽  
Vol 24 (S1) ◽  
Author(s):  
S. Stevens Negus ◽  
Ember M. Morrissey ◽  
Marisa B. Rosenberg ◽  
Ahmad Altarifi ◽  
K. Cheng ◽  
...  
Keyword(s):  
Opioid Antagonist ◽  
Opioid Agonist ◽  
Kappa Opioid ◽  
Kappa Opioid Agonist ◽  
Self Stimulation

Synthesis of tritium labelled (-)-U50,488, a selective kappa opioid agonist

1989 ◽  
Vol 27 (5) ◽  
pp. 577-582 ◽  
Author(s):  
Andrew Thurkauf ◽  
Brian De Gosta ◽  
Kenner C. Rice
Keyword(s):  
Opioid Agonist ◽  
Kappa Opioid ◽  
Kappa Opioid Agonist

scholarly journals Synergistic antidepressant-like effects between a kappa opioid antagonist (LY2444296) and a delta opioid agonist (ADL5859) in the mouse forced swim test

2016 ◽  
Vol 781 ◽  
pp. 53-59 ◽  
Author(s):  
Peng Huang ◽  
Julia Tunis ◽  
Christopher Parry ◽  
Ronald Tallarida ◽  
Lee-Yuan. Liu-Chen
Keyword(s):  
Forced Swim Test ◽  
Opioid Antagonist ◽  
Opioid Agonist ◽  
Kappa Opioid ◽  
Swim Test ◽  
Forced Swim
Sign in / Sign up

Export Citation Format

Share Document